Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...
Novo Nordisk reported better-than-expected third-quarter sales for its weight-loss drug Wegovy, calming investor concerns ...
Novo Nordisk's sales of Wegovy surpassed expectations, calming investor concerns about competition from Eli Lilly. Shares ...
Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
The weight-loss drug users and doctors whom The Times spoke to for this ... Last week, the Food and Drug Administration ...
After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company’s oral small molecule GLP1 drug ...
Reuters on MSN3d
Analysis-Americans hungry for weight-loss drugs grapple with supply and insurance hurdlesAmericans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk's weight-loss and diabetes drugs but cannot ...
Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss medicine Wegovy this Wednesday. Lilly attributed the shortfall to a logistical ...
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback